DelveInsight’s ‘Postoperative Pain-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the postoperative pain, historical and forecasted epidemiology as well as the postoperative pain market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Postoperative Pain market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM postoperative pain market size from 2018 to 2030. The Report also covers current postoperative pain treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018–2030
Postoperative Pain Overview
Postoperative Pain is an anticipated and temporary increase in background pain that occurs following surgical procedures. It is a type of pain that typically lasts less than a few days to months or pain directly related to soft tissue damage such as a sprained ankle or a paper cut. The pain is of short duration, but it gradually resolves as the injured tissues heal. It is further classified as acute and chronic pain based on the duration.
The Interagency Pain Research Coordinating Committee (IPRCC) of the US Department of Health and Human Services describes acute pain as “an expected physiologic experience to noxious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.”
The intensity, quality, and duration of postoperative pain are affected mainly by the location, type, and duration of the surgical procedure; type and extent of the incision and surgical trauma; the physical and mental state of the patient including the patient’s approach to pain; preoperative psychological and pharmacological preparation; type of anesthesia; pain management before and after the surgical procedure; incidence of surgical complications; and quality of postoperative care.
Postoperative Pain Diagnosis
In order to treat pain efficiently, it needs to be properly diagnosed, measured, and documented. Only by this, optimal analgesia may be achieved, which is a mild and tolerable sensation of pressure in the surgical wound with minimal adverse effects. Proper diagnosis of the type and intensity of pain is crucial for an adequate and targeted treatment of acute pain. It requires a highly professional approach in terms of expertise, psychology, and ethics. The examination of acute postoperative pain involved medical history, physical examination, and specific evaluation of pain; measuring pain; rating scales provide a simple means for patients to rate pain intensity; verbal expression to assess the intensity of pain and other assessments.
Continued in the report…..
Postoperative Pain Treatment
Postoperative pain management aims not only to decline pain intensity but also to increase patient comfort and to improve postoperative outcomes. Pharmacologic therapies for pain include drugs from several drug classes. Pain-relieving analgesics include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, and acetaminophen. Providers also elect to manage acute pain with benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids. Topical agents, such as capsaicin and lidocaine are also used.
Nonpharmacologic therapies for pain are becoming more widely used to avoid problems associated with pharmacologic therapies. Examples of nonpharmacologic therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM).
Continued in the report…..
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the total number of surgical procedures, total number of incident cases of postoperative pain, and severity-specific incident cases of postoperative pain scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Key Findings
The epidemiology segment also provides the Postoperative pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Postoperative pain report encloses the detailed analysis of Postoperative pain marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Postoperative pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.
Postoperative Pain Marketed Drugs
Exparel: Pacira Pharmaceuticals
Exparel (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired period.
Products detail in the report…
Anjeso: Baudax Bio
ANJESO (meloxicam) injection is a proprietary, long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis. Anjeso (meloxicam) injection was approved by the US Food and Drug Administration (FDA) in February 2020 for use in adults to manage moderate to severe pain, alone or in combination with non-NSAID analgesics. Because of the delayed onset of analgesia, Anjeso alone is not recommended for use when a rapid onset of analgesia is required.
Products detail in the report…
Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals
Dsuvia is an opioid agonist that contains sufentanil and is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. Dsuvia is administered in the form of the tablet sublingually to the patient. However, the intensity of pain must be severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It was approved in 2018 in the US and EU for the management of moderate-to-severe acute pain in medically supervised settings for adult patients. In January 2021, AcelRx announced an investigator-initiated study with University Hospitals Cleveland Medical Center to evaluate the postoperative use of the drug in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol.
Products detail in the report…
List to be continued in the report…
Postoperative Pain Emerging Drugs
CR845/Difelikefalin: Cara Therapeutics
Cara Therapeutics is developing the first peripherally acting kappa opioid receptor agonist (KORA) called CR845. The drug is a potent peripheral kappa-opioid receptor agonist with high selectivity over other opioid receptors in the body. The degree of kappa receptor selectivity displayed by CR845 is best-in-class compared to all other previously developed compounds for this therapeutic target.
Products detail in the report…
VVZ-149 Injections: Vivozon, Inc.
Vivozon, Inc. is developing VVZ-149, a drug with a new mechanism-based nonnarcotic and non-NSAID analgesic. VVZ-149 is currently being evaluated in clinical trials (Korea and USA) in an IV infusion setting to treat postoperative pain following laparoscopic gastrectomy or laparoscopic colorectomy and lumbar radiculopathy (Sciatica). The company is preparing a comprehensive data package to initiate the GLP toxicology studies of the oral VVZ-149.
Products detail in the report…
F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell
The MedinCell’s partner, Arthritis Innovation Corporation (AIC)’s drug F14 (sustained-release celecoxib)/ mdc-CWM (Celecoxib), is an extended-release intra-articular injectable drug for postoperative pain and inflammation treatment in clinical testing which uses sustained local delivery of an NSAID after total knee replacement (TKR) to manage pain and inflammation as an alternative to oral NSAIDs or narcotics
Products detail in the report…
List to be continued in the report…
The United States holds a major share of the postoperative pain market as compared to other countries of the 7MM.
The effective relief of pain is of the utmost importance to treating patients undergoing surgery. Pain relief has significant physiological benefits; hence, monitoring of pain relief is increasingly becoming a crucial postoperative quality measure. The goal for postoperative pain management is to reduce or eliminate pain and discomfort with a minimum of side effects. In recent years, extensive changes have been observed in the postoperative pain management market. Opioid replacement with other more beneficiary approaches has been in talk. Opioid was a gold standard but is now being replaced by multimodal analgesia (MMA) models. Even several top agencies like the US Department of Health and Human Services (USDHHS) are showing their primary focus in multimodal pain management. MMA helps to increase efficacy while minimizing adverse effects since different targets are approached with lesser doses. In ambulatory patient care also MMA model is capable of achieving adequate pain relief to discharge the patient earlier.
In spite of the growing awareness of the value of multimodal pain management plans, opioid monotherapy remains the foundation of postsurgical pain therapy. Opioids that are delivered by the patient-controlled analgesia are the support of systemic analgesia for the treatment of moderate-to-severe postoperative pain. Analgesics that act by different mechanisms and at various receptor sites are normally combined to produce additive or synergistic pain relief and can reduce opioid use. Regimens that use nonopioid analgesics include paracetamol, NSAIDs (cyclo-oxygenase inhibitors), alpha 2 agonists (clonidine, dexmedetomidine), gabapentin, pregabalin, Ketamine, Lignocaine infusions, and Peripheral nerve blocks, local anesthetic wound infiltration, and continuous wound infusion techniques.
Pain relief after surgery continues to be a major medical challenge. Poorly managed postoperative pain may delay discharge and recovery, and result in the patient's inability to participate in rehabilitation programs, leading to poor outcomes. There is a major unmet need for the recent advances that include a better understanding of pain mechanisms, physiology, and pharmacology, the publication of guidelines, establishment of acute pain services (APSs), initiatives such as ‘pain as the fifth vital sign’ and availability of new drugs and devices. However, these advances have not led to any major improvements, and the under-treatment of postoperative pain continues as a considerable problem worldwide. Overall, the postoperative pain therapeutics market is further expected to increase in the forecast period (2021–2030).
Key Findings
The United States Market Outlook
This section provides the total postoperative pain market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total postoperative pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total postoperative pain market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the postoperative pain market or expected to get launched in the market during the study period 2018–2030. The analysis covers postoperative pain market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Postoperative pain emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive and market Intelligence analysis of the Postoperative pain market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
1. Report Introduction
2. Postoperative Pain Market Overview at a Glance
2.1. Market Share (%) Distribution of Postoperative Pain in 2018
2.2. Market Share (%) Distribution of Postoperative Pain in 2030
3. Postoperative Pain Market: Future Perspective
4. Executive Summary of Postoperative Pain
5. Disease Background and Overview
5.1. Introduction
5.2. Transition from Acute to Chronic Pain
5.2.1. Elective or Planned Procedures
5.2.2. Common Types of Acute Postoperative Pains
5.3. Pathophysiology of Acute Pain
5.3.1. Formation of reflexes in postoperative pain
5.3.1.1. Segmental reflexes
5.3.1.2. Suprasegmental reflexes
5.3.1.3. Cortical responses
5.3.2. Negative effects of postoperative pain on various organ systems
5.3.2.1. Changes in respiratory functions
5.3.2.2. Cardiovascular changes
5.3.2.3. Gastrointestinal and urinary changes
5.3.2.4. Neuroendocrine and metabolic changes
5.3.3. Psychological effects of postoperative pain
5.3.4. Late effects of insufficient postoperative analgesia
5.3.5. Chronic postoperative pain
5.4. Factors affecting postoperative pain
5.5. Diagnosis of Postoperative Pain
5.5.1. Medical history, physical examination, and specific evaluation of pain
5.5.2. Measuring pain
5.5.3. Various Grading Scales used for Diagnosis of Acute Pain
5.5.3.1. Visual Analogue Scale
5.5.3.2. Verbal Rating Scale
5.5.3.3. Graded Chronic Pain Scale (GCPS)
5.5.3.4. Numeric Rating Scale (NRS)
5.5.4. Verbal methods of pain assessment
5.5.5. Multidimensional methods of pain assessment
5.5.6. Nonverbal methods of pain assessment
5.5.7. Diagnostic Algorithm
5.5.8. Guidelines
5.5.8.1. Guidelines on the Management of Postoperative Pain
5.5.8.2. Goals and Elements of the Initial Assessment
5.6. Treatment
5.6.1. Pharmacological Therapies
5.6.2. Multimodal analgesia
5.6.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.6.3.1. Nonselective COX inhibitors
5.6.3.2. Preferential COX-2 inhibitors
5.6.3.3. Selective COX-2 inhibitors – coxibs
5.6.4. Opioids
5.6.4.1. Weak opioid analgesics
5.6.4.2. Strong opioid analgesics
5.6.5. Non-opioid analgesics
5.6.5.1. Paracetamol (acetaminophen)
5.6.5.2. Metamizole
5.6.6. Procedure-specific analgesia
5.6.6.1. Discharge planning
5.6.7. Regional anesthesia
5.6.8. Non-Pharmacological Methods to Treat Acute Pain
5.6.8.1. Cognitive dysfunction
5.6.8.2. Herbal medicine
5.6.8.3. Homeopathy
5.6.8.4. Meditation
5.6.9. Physical methods
5.6.9.1. Cold
5.6.9.2. Heat
5.6.9.3. Transcutaneous electrical nerve stimulation (TENS) in Acute Post-Operative Pain
5.6.9.4. Acupuncture
5.6.9.5. Hypnosis
5.6.9.6. Immobilization
5.6.9.7. Massage
5.6.10. Intravenous Patient-Controlled Analgesia (PCA)
5.6.10.1. Patient-Controlled Epidural Analgesia
5.6.11. Nerve Blocks
5.6.12. Pediatric Pain Management
5.6.13. Treatment Algorithm for Acute Postoperative Pain
5.6.14. Guidelines for Acute Pain
5.6.14.1. Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy (2017)
5.6.14.2. Management of Postoperative Pain: A Clinical Practice Guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council (2017)
5.6.15. Recommendations for Pre- and Intra-operative Pain Management by The European Society of Regional Anesthesia and Pain Therapy
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Total number of Incident cases of Postoperative Pain in the 7MM
6.4. Epidemiology of Postoperative Pain
6.5. United States
6.5.1. Total number of surgical procedures in the US
6.5.2. Total number of Incident cases of Postoperative Pain in the US
6.5.3. Severity-specific incident cases of Postoperative Pain in the US
6.6. EU5
6.6.1. Germany
6.6.1.1. Total number of surgical procedures in Germany
6.6.1.2. Total number of Incident cases of Postoperative Pain in Germany
6.6.1.3. Severity-specific incident cases of Postoperative Pain in Germany
6.6.2. France
6.6.2.1. Total number of surgical procedures in France
6.6.2.2. Total number of Incident cases of Postoperative Pain in France
6.6.2.3. Severity-specific incident cases of Postoperative Pain in France
6.6.3. Italy
6.6.3.1. Total number of surgical procedures in Italy
6.6.3.2. Total number of Incident cases of Postoperative Pain in Italy
6.6.3.3. Severity-specific incident cases of Postoperative Pain in Italy
6.6.4. Spain
6.6.4.1. Total number of surgical procedures in Spain
6.6.4.2. Total number of Incident cases of Postoperative Pain in Spain
6.6.4.3. Severity-specific incident cases of Postoperative Pain in Spain
6.6.5. United Kingdom
6.6.5.1. Total number of surgical procedures in the UK
6.6.5.2. Total number of Incident cases of Postoperative Pain in the UK
6.6.5.3. Severity-specific incident cases of Postoperative Pain in the UK
6.7. Japan
6.7.1. Total number of surgical procedures in Japan
6.7.2. Total number of Incident cases of Postoperative Pain in Japan
6.7.3. Severity-specific incident cases of Postoperative Pain in Japan
7. Patient Journey
8. Marketed Drugs
8.1. Marketed Drugs Key-cross Competition
8.2. Enanplus/Takudex (Dexketoprofen/Tramadol): Menarini Group/Guidotti Farma
8.2.1. Product Description
8.2.2. Regulatory Milestones
8.2.3. Other Developmental activities
8.2.4. Clinical Development
8.2.5. Clinical Trials Information
8.2.6. Safety and Efficacy
8.2.7. Product Profile
8.3. Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals
8.3.1. Product Description
8.3.2. Regulatory Milestones
8.3.3. Other Developmental activities
8.3.4. Clinical Development
8.3.5. Clinical Trials Information
8.3.6. Safety and Efficacy
8.3.7. Product Profile
8.4. Zalviso: AcelRx Pharmaceuticals
8.4.1. Product Description
8.4.2. Regulatory Milestones
8.4.3. Other Developmental activities
8.4.4. Clinical Development
8.4.5. Clinical Trials Information
8.4.6. Safety and Efficacy
8.4.7. Product Profile
8.5. Olinvyk (Olinvo) (oliceridine): Trevena, Inc.
8.5.1. Product Description
8.5.2. Regulatory Milestones
8.5.3. Other Development Activities
8.5.4. Clinical Development
8.5.5. Clinical Trials Information
8.5.6. Safety and Efficacy
8.5.7. Product Profile
8.6. Zynrelef (HTX-011): Heron Therapeutics
8.6.1. Product Description
8.6.2. Regulatory Milestones
8.6.3. Other Developmental Activities
8.6.4. Clinical Development
8.6.5. Clinical Trials Information
8.6.6. Safety and Efficacy
8.6.7. Product Profile
8.7. Xaracoll: Innocoll Pharmaceuticals
8.7.1. Product Description
8.7.2. Regulatory Milestones
8.7.3. Other Developmental activities
8.7.4. Clinical Development
8.7.5. Clinical Trials Information
8.7.6. Safety and Efficacy
8.7.7. Product Profile
8.8. Posimir (bupivacaine solution): DURECT Corporation
8.8.1. Product Description
8.8.2. Regulatory Milestones
8.8.3. Other Developmental activities
8.8.4. Clinical Development
8.8.5. Clinical Trials Information
8.8.6. Safety and Efficacy
8.8.7. Product Profile
8.9. Exparel: Pacira Pharmaceuticals
8.9.1. Product Description
8.9.2. Regulatory Milestones
8.9.3. Other Developmental activities
8.9.4. Clinical Development
8.9.5. Clinical Trials Information
8.9.6. Safety and Efficacy
8.9.7. Product Profile
8.10. Anjeso: Baudax Bio
8.10.1. Product Description
8.10.2. Regulatory Milestones
8.10.3. Other Development Activities
8.10.4. Clinical Development
8.10.5. Clinical Trials Information
8.10.6. Safety and Efficacy
8.10.7. Product Profile
8.11. Prolensa (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb
8.11.1. Product Description
8.11.2. Regulatory Milestones
8.11.3. Clinical Development
8.11.4. Clinical Trials Information
8.11.5. Safety and Efficacy
8.11.6. Product Profile
8.12. Dextenza: Ocular Therapeutix
8.12.1. Product Description
8.12.2. Regulatory Milestones
8.12.3. Other Developmental activities
8.12.4. Clinical Development
8.12.5. Clinical Trials Information
8.12.6. Safety and Efficacy
8.12.7. Product Profile
8.13. Inveltys: Kala Pharmaceuticals, Inc.
8.13.1. Product Description
8.13.2. Regulatory Milestones
8.13.3. Other Developmental activities
8.13.4. Clinical Development
8.13.5. Clinical Trials Information
8.13.6. Safety and Efficacy
8.13.7. Product Profile
8.14. Penthrox: Medical Developments International Ltd (MVP)
8.14.1. Product Description
8.14.2. Regulatory Milestones
8.14.3. Other Developmental activities
8.14.4. Clinical Development
8.14.5. Clinical Trials Information
8.14.6. Safety and Efficacy
8.14.7. Product Profile
8.15. Lotemax SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
8.15.1. Product Description
8.15.2. Regulatory Milestones
8.15.3. Safety and Efficacy
8.15.4. Product Profile
8.16. Maxigesic: Hyloris Pharmaceuticals/AFT Pharmaceuticals
8.16.1. Product Description
8.16.2. Regulatory Milestone
8.16.3. Other Developmental Activities
8.16.4. Clinical Development
8.16.5. Clinical Trials Information
8.16.6. Safety and Efficacy
8.16.7. Product Profile
9. Emerging Drugs
9.1. Key Cross Competition
9.2. CR845/Difelikefalin: Cara Therapeutics
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Clinical Trials Information
9.2.5. Safety and Efficacy
9.2.6. Product Profile
9.3. VVZ-149 Injections: Vivozon, Inc.
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Clinical Trials Information
9.3.5. Safety and Efficacy
9.3.6. Product Profile
9.4. Tramadol IV: Avenue Therapeutics, Inc.
9.4.1. Product Description
9.4.2. Other Developmental Activities
9.4.3. Clinical Development
9.4.4. Clinical Trials Information
9.4.5. Safety and Efficacy
9.4.6. Product Profile
9.5. F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell
9.5.1. Product Description
9.5.2. Other Developmental Activities
9.5.3. Clinical Development
9.5.4. Clinical Trials Information
9.5.5. Safety and Efficacy
9.5.6. Product Profile
9.6. Nefopam hydrochloride and paracetamol: Unither Pharmaceuticals
9.6.1. Product Description
9.6.2. Clinical Development
9.6.3. Clinical Trials Information
9.6.4. Product Profile
9.7. Co-crystal E-58425 (Tramadol/Celecoxib): Esteve Pharmaceuticals
9.7.1. Product Description
9.7.2. Other Developmental Activities
9.7.3. Clinical Development
9.7.4. Clinical Trials Information
9.7.5. Safety and Efficacy
9.7.6. Product Profile
9.8. APP13007: Formosa Pharmaceuticals
9.8.1. Drug Description
9.8.2. Regulatory Milestones
9.8.3. Clinical Development
9.8.4. Clinical Trials Information
9.8.5. Safety and Efficacy
9.8.6. Product Profile
9.9. NTM-001 (Ketorolac Pre-Mixed Bag): Neumentum Pharmaceuticals
9.9.1. Product Description
9.9.2. Other Developmental Activities
9.9.3. Clinical Developmental Activities
9.9.4. Safety and Efficacy
9.9.5. Product Profile
9.10. ACP-044: Acadia Pharmaceuticals Inc.
9.10.1. Product Description
9.10.2. Other Developmental Activities
9.10.3. Clinical Development
9.10.4. Clinical Trials Information
9.10.5. Product Profile
9.11. NVK-009 (Pregabalin and Acetaminophen): Nevakar, Inc.
9.11.1. Product Description
9.11.2. Clinical Development
9.11.3. Clinical Trials Information
9.11.4. Product Profile
9.12. TLC590: Taiwan Liposome Company (TLC)
9.12.1. Product Description
9.12.2. Other Developmental Activities
9.12.3. Clinical Development
9.12.4. Clinical Trials Information
9.12.5. Safety and Efficacy
9.12.6. Product Profile
9.13. MR-107A-01: Viatris Inc. (formerly known as Mylan Inc.)
9.13.1. Product Description
9.13.2. Other Developmental Activities
9.13.3. Clinical Development
9.13.4. Clinical Trials Information
9.13.5. Product Profile
9.14. TPU-006 (Dexmedetomidine Transdermal System (DMTS)): Teikoku Pharma USA, Inc.
9.14.1. Product Description
9.14.2. Other Developmental Activities
9.14.3. Clinical Development
9.14.4. Clinical Trials Information
9.14.5. Safety and Efficacy
9.14.6. Product Profile
9.15. SAF312: Novartis Pharmaceuticals
9.15.1. Product Description
9.15.2. Clinical Development
9.15.3. Clinical Trials Information
9.15.4. Safety and Efficacy
9.15.5. Product Profile
9.16. OCS-01: Oculis
9.16.1. Product Description
9.16.2. Other Developmental Activities
9.16.3. Clinical Development
9.16.4. Clinical Trials Information
9.16.5. Safety and Efficacy
9.16.6. Product Profile
9.17. PRF110: PainReform LTD
9.17.1. Product Description
9.17.2. Other Developmental Activities
9.17.3. Clinical Development
9.17.4. Clinical Trials Information
9.17.5. Safety and Efficacy
9.17.6. Product Profile
9.18. Vocacapsaicin (CA-008): Concentric Analgesics
9.18.1. Product Description
9.18.2. Other Developmental Activities
9.18.3. Clinical Development
9.18.4. Clinical Trials Information
9.18.5. Safety and Efficacy
9.18.6. Product Profile
9.19. Nepafenac PPDS/Nepafenac Evolute: Mati Therapeutics Inc.
9.19.1. Product Description
9.19.2. Other Developmental Activities
9.19.3. Clinical Development
9.19.4. Clinical Trials Information
9.19.5. Safety and Efficacy
9.19.6. Product Profile
10. Postoperative Pain: Seven Major Market Analysis
10.1. Key Findings
10.2. Methodology of Postoperative Pain Market
10.3. Market Size of Postoperative Pain in the 7MM Countries
10.4. Market Size of Postoperative Pain by Therapies in the 7MM Countries
10.5. Comparison of 7MM Postoperative Pain Market
10.6. Discharge Prescription Pattern of Various Analgesic in Postoperative Pain among the United States and EU
10.7. Emerging Drug Analysis
10.8. 7MM Market Outlook
10.9. United States Market Size
10.9.1. Total Market Size of Postoperative Pain in the United States
10.9.2. Market Size by Therapies of Postoperative Pain in the United States
10.10. EU-5 Market Size
10.10.1. Germany
10.10.1.1. Total Market size of Postoperative Pain in Germany
10.10.1.2. Market Size by Therapies of Postoperative Pain in Germany
10.10.2. France
10.10.2.1. Total Market size of Postoperative Pain in France
10.10.2.2. Market Size of Postoperative Pain by Therapies in France
10.10.3. Italy
10.10.3.1. Total Market Size of Postoperative Pain in Italy
10.10.3.2. Market Size of Postoperative Pain by Therapies in Italy
10.10.4. Spain
10.10.4.1. Total Market Size of Postoperative Pain in Spain
10.10.4.2. Market Size of Postoperative Pain by Therapies in Spain
10.10.5. United Kingdom
10.10.5.1. Total Market Size of postoperative pain in the United Kingdom
10.10.5.2. Market Size of Postoperative Pain by Therapies in the United Kingdom
10.11. Japan
10.11.1. Total Market Size of Postoperative Pain in Japan
10.11.2. Market Size of Postoperative Pain by Therapies in Japan
11. KOL Views
11.1. US KOL Views
11.2. EU5 and Japan KOL Views
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15. Unmet Needs
16. Reimbursement and Market Access
17. Appendix
17.1. Bibliography
17.2. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Table
Table 1: Summary of Postoperative Pain, Market, Epidemiology, and Key Events (2018–2030)
Table 2: Common Types of Pain (related to acute Postoperative Pain)
Table 3: Graded Chronic Pain Scale (GCPS)
Table 4: Unidimensional Pain Assessment Tools
Table 5: Multidimensional Pain Assessment Tools
Table 6: Preoperative Assessment and Patient Education Recommendations
Table 7: Postoperative Assessment and Patient Education Recommendations
Table 8: Perioperative Pain Management Considerations and Recommendations
Table 9: Recommended: Pre- and intra-operative interventions for Inguinal Hernia Repair
Table 10: Recommended: Pre- and intra-operative interventions for Hallux Valgus Repair Surgery
Table 11: Recommendations: Pain management after complex spine surgery
Table 12: Overall recommendations for pain management in patients undergoing elective caesarean section
Table 13: Total number of Incident cases of Postoperative Pain in the 7MM (2018–2030) (in ‘000’)
Table 14: Total number of surgical procedures in the US (2018–2030) (in ‘000’)
Table 15: Total number of Incident cases of Postoperative Pain in the US (2018–2030) (in ‘000’)
Table 16: Severity-specific incident cases of Postoperative Pain in the US (2018–2030) (in ‘000’)
Table 17: Total number of surgical procedures in Germany (2018–2030) (in ‘000’)
Table 18: Total number of Incident cases of Postoperative Pain in Germany (2018–2030) (in ‘000’)
Table 19: Severity-specific incident cases of Postoperative Pain in Germany (2018–2030) (in ‘000’)
Table 20: Total number of surgical procedures in France (2018–2030) (in ‘000’)
Table 21: Total number of Incident cases of Postoperative Pain in France (2018–2030) (in ‘000’)
Table 22: Severity-specific incident cases of Postoperative Pain in France (2018–2030) (in ‘000’)
Table 23: Total number of surgical procedures in Italy (2018–2030) (in ‘000’)
Table 24: Total number of Incident cases of Postoperative Pain in Italy (2018–2030) (in ‘000’)
Table 25: Severity-specific incident cases of Postoperative Pain in Italy (2018–2030) (in ‘000’)
Table 26: Total number of surgical procedures in Spain (2018–2030) (in ‘000’)
Table 27: Total number of Incident cases of Postoperative Pain in Spain (2018–2030) (in ‘000’)
Table 28: Severity-specific incident cases of Postoperative Pain in Spain (2018–2030) (in ‘000’)
Table 29: Total number of surgical procedures in the UK (2018–2030) (in ‘000’)
Table 30: Total number of Incident cases of Postoperative Pain in the UK (2018–2030) (in ‘000’)
Table 31: Severity-specific incident cases of Postoperative Pain in the UK (2018–2030) (in ‘000’)
Table 32: Total number of surgical procedures in Japan (2018–2030) (in ‘000’)
Table 33: Total number of Incident cases of Postoperative Pain in Japan (2018–2030) (in ‘000’)
Table 34: Severity-specific incident cases of Postoperative Pain in Japan (2018–2030) (in ‘000’)
Table 35: Comparison of Marketed Drugs
Table 36: Dexketoprofen/Tramadol, Clinical Trial Description, 2021
Table 37: Dsuvia, Clinical Trial Description, 2021
Table 38: Zalviso, Clinical Trial Description, 2021
Table 39: Olinvyk, Clinical Trial Description, 2021
Table 40: Zynrelef (HTX-011), Clinical Trial Description, 2021
Table 41: XaraColl, Clinical Trial Description, 2021
Table 42: Posimir (bupivacaine solution), Clinical Trial Description, 2021
Table 43: Exparel, Clinical Trial Description, 2021
Table 44: ANJESO (N1539), Clinical Trial Description, 2021
Table 45: Prolensa (bromfenac ophthalmic solution) 0.07%, Clinical Trial Description, 2021
Table 46: Dextenza, Clinical Trial Description, 2021
Table 47: Inveltys, Clinical Trial Description, 2021
Table 48: Penthrox, Clinical Trial Description, 2021
Table 49: Maxigesic, Clinical Trial Description, 2021
Table 50: Comparison of emerging drugs under development (1)
Table 51: Comparison of emerging drugs under development (2)
Table 52: Comparison of emerging drugs under development (3)
Table 53: Comparison of emerging drugs under development (4)
Table 54: CR845, Clinical Trial Description, 2021
Table 55: VVZ-149, Clinical Trial Description, 2021
Table 56: Tramadol, Clinical Trial Description, 2021
Table 57: F14 (sustained release celecoxib), Clinical Trial Description, 2021
Table 58: Nefopam hydrochloride 30 mg /Paracetamol 500 mg X2 , Clinical Trial Description, 2021
Table 59: Co-crystal E-58425 (Tramadol/Celecoxib), Clinical Trial Description, 2021
Table 60: APP13007, Clinical Trial Description, 2021
Table 61: ACP-044, Clinical Trial Description, 2021
Table 62: NVK-009, Clinical Trial Description, 2021
Table 63: TLC590, Clinical Trial Description, 2021
Table 64: MR-107A-01, Clinical Trial Description, 2021
Table 65: TPU-006, Clinical Trial Description, 2021
Table 66: SAF312, Clinical Trial Description, 2021
Table 67: OCS-01, Clinical Trial Description, 2021
Table 68: PRF 110, Clinical Trial Description, 2021
Table 69: Vocacapsaicin (CA-008), Clinical Trial Description, 2021
Table 70: Nepafenac PPDS, Clinical Trial Description, 2021
Table 71: Market size of Postoperative Pain in the 7MM, in USD million (2018–2030)
Table 72: Market size of Postoperative Pain by therapies in the 7MM, in USD million (2018–2030)
Table 73: Market size of Postoperative Pain in the United States, USD million (2018–2030)
Table 74: Market size of Postoperative Pain by therapies in the US, in USD million (2018–2030)
Table 75: Market size of Postoperative Pain in Germany, in USD million (2018–2030)
Table 76: Market size of Postoperative Pain by therapies in Germany, in USD million (2018–2030)
Table 77: Market size of Postoperative Pain in France, in USD million (2018–2030)
Table 78: Market size of Postoperative Pain by therapies in France, in USD million (2018–2030)
Table 79: Market size of Postoperative Pain in Italy, in USD million (2018–2030)
Table 80: Market size of Postoperative Pain by therapies in Italy, in USD million (2018–2030)
Table 81: Market size of Postoperative Pain in Spain, in USD million (2018–2030)
Table 82: Market size of Postoperative Pain by therapies in Spain, in USD million (2018–2030)
Table 83: Market Size of Postoperative Pain in the UK, in USD million (2018–2030)
Table 84: Market size of Postoperative Pain by therapies in the UK, in USD million (2018–2030)
Table 85: Market Size of Postoperative Pain in Japan, in USD million (2018–2030)
Table 86: Market size of Postoperative Pain by therapies in Japan, in USD million (2018–2030)
List of Figures
Figure 1: Types of Pain
Figure 2: Four basic components for Postoperative Pain
Figure 3: Wong-Baker Faces Pain Rating Scale
Figure 4: Progression from Acute to Chronic Pain
Figure 5: Progression from Acute to Chronic Pain
Figure 6: Afferent Nociceptive Pathway
Figure 7: Efferent Nociceptive pathway
Figure 8: Negative effects of Postoperative Pain on the various organ system
Figure 9: Efferent Nociceptive pathway
Figure 10: Present Pain Intensity (PPI)
Figure 11: Present Pain Intensity (PPI)
Figure 12: Progression of regional anesthetic applications into formal acute pain medicine programs
Figure 13: Common techniques for post-operative pain management
Figure 14: Treatment Algorithm for Acute Postoperative Pain
Figure 15: Total number of Incident cases of Postoperative Pain in the 7MM (2018–2030)
Figure 16: Total number of surgical procedures in the US (2018–2030)
Figure 17: Total number of Incident cases of Postoperative Pain in the US (2018–2030)
Figure 18: Severity-specific incident cases of Postoperative Pain in the US (2018–2030)
Figure 19: Total number of surgical procedures in Germany (2018–2030)
Figure 20: Total number of Incident cases of Postoperative Pain in Germany (2018–2030)
Figure 21: Severity-specific incident cases of Postoperative Pain in Germany (2018–2030)
Figure 22: Total number of surgical procedures in France (2018–2030)
Figure 23: Total number of Incident cases of Postoperative Pain in France (2018–2030)
Figure 24: Severity-specific incident cases of Postoperative Pain in France (2018–2030)
Figure 25: Total number of surgical procedures in Italy (2018–2030)
Figure 26: Total number of Incident cases of Postoperative Pain in Italy (2018–2030)
Figure 27: Severity-specific incident cases of Postoperative Pain in Italy (2018–2030)
Figure 28: Total number of surgical procedures in Spain (2018–2030)
Figure 29: Total number of Incident cases of Postoperative Pain in Spain (2018–2030)
Figure 30: Severity-specific incident cases of Postoperative Pain in Spain (2018–2030)
Figure 31: Total number of surgical procedures in the UK (2018–2030)
Figure 32: Total number of Incident cases of Postoperative Pain in the UK (2018–2030)
Figure 33: Severity-specific incident cases of Postoperative Pain in the UK (2018–2030)
Figure 34: Total number of surgical procedures in Japan (2018–2030)
Figure 35: Total number of Incident cases of Postoperative Pain in Japan (2018–2030)
Figure 36: Severity-specific incident cases of Postoperative Pain in Japan (2018–2030)
Figure 37: Patient Journey
Figure 38: Market size of Postoperative Pain in the 7MM, in USD million (2018–2030)
Figure 39: Market size of Postoperative Pain by therapies in the 7MM, in USD million (2018–2030)
Figure 40: A representation of intra- and postoperative care considerations
Figure 41: Market size of Postoperative Pain in the United States, USD millions (2018–2030)
Figure 42: Market size of Postoperative Pain by therapies in the US, in USD million (2018–2030)
Figure 43: Market size of Postoperative Pain in Germany, USD million (2018–2030)
Figure 44: Market size of Postoperative Pain by therapies in Germany, in USD million (2018–2030)
Figure 45: Market size of Postoperative Pain in France, USD million (2018–2030)
Figure 46: Market size of Postoperative Pain by therapies in France, in USD million (2018–2030)
Figure 47: Market size of Postoperative Pain in Italy, USD million (2018–2030)
Figure 48: Market size of Postoperative Pain by therapies in Italy, in USD million (2018–2030)
Figure 49: Market size of Postoperative Pain in Spain, USD million (2018–2030)
Figure 50: Market size of Postoperative Pain by therapies in Spain, in USD million (2018–2030)
Figure 51: Market Size of Postoperative Pain in the UK, USD million (2018–2030)
Figure 52: Market size of Postoperative Pain by therapies in the UK, in USD million (2018–2030)
Figure 53: Market Size of Postoperative Pain in Japan, USD million (2018–2030)
Figure 54: Market size of Postoperative Pain by therapies in Japan, in USD million (2018–2030)
Figure 55: Market Drivers
Figure 56: Market Barriers
Figure 57: SWOT Analysis
Figure 58: Unmet Needs
• Menarini Group/Guidotti Farma
• AcelRx Pharmaceuticals
• AcelRx Pharmaceuticals
• Trevena, Inc.
• Heron Therapeutics
• Innocoll Pharmaceuticals
• DURECT Corporation
• Pacira Pharmaceuticals
• Baudax Bio
• Bausch & Lomb
• Ocular Therapeutix
• Kala Pharmaceuticals, Inc.
• Medical Developments International Ltd (MVP)
• Bausch & Lomb
• Hyloris Pharmaceuticals/AFT Pharmaceuticals
• Cara Therapeutics
• Vivozon, Inc.
• Avenue Therapeutics, Inc.
• Arthritis Innovation Corporation/MedinCell
• Unither Pharmaceuticals
• Esteve Pharmaceuticals
• Formosa Pharmaceuticals
• Neumentum Pharmaceuticals
• Acadia Pharmaceuticals Inc.
• Nevakar, Inc.
• Taiwan Liposome Company (TLC)
• Viatris Inc. (formerly known as Mylan Inc.)
• Teikoku Pharma USA, Inc.
• Novartis Pharmaceuticals
• Oculis
• PainReform LTD
• Concentric Analgesics
• Mati Therapeutics Inc.
